Top

Published in:

Open Access 01-12-2018 | Review

Proton beam therapy for cancer in the era of precision medicine

Authors: Man Hu, Liyang Jiang, Xiangli Cui, Jianguang Zhang, Jinming Yu

Published in: Journal of Hematology & Oncology | Issue 1/2018

Abstract

Precision radiotherapy, which accurately delivers the dose on a tumor and confers little or no irradiation to the surrounding normal tissue and organs, results in maximum tumor control and decreases the toxicity to the utmost extent. Proton beam therapy (PBT) provides superior dose distributions and has a dosimetric advantage over photon beam therapy. Initially, the clinical practice and study of proton beam therapy focused on ocular tumor, skull base, paraspinal tumors (chondrosarcoma and chordoma), and unresectable sarcomas, which responded poorly when treated with photon radiotherapy. Then, it is widely regarded as an ideal mode for reirradiation and pediatrics due to reducing unwanted side effects by lessening the dose to normal tissue. During the past decade, the application of PBT has been rapidly increasing worldwide and gradually expanding for the treatment of various malignancies. However, to date, the role of PBT in clinical settings is still controversial, and there are considerable challenges in its application. We systematically review the latest advances of PBT and the challenges for patient treatment in the era of precision medicine.

Mohan R, Grosshans D. Proton therapy - present and future. Adv Drug Deliv Rev. 2017;109:26–44 https://doi.org/10.1016/j.addr.2016.11.006.PubMedCrossRef

Wilson RR. Radiological use of fast protons. Radiology. 1946;47:487–91 https://doi.org/10.1148/47.5.487.PubMedCrossRef

Lawrence JH, Tobias CA, Born JL, RK MCOMBS, Roberts JE, Anger HO, et al. Pituitary irradiation with high-energy proton beams: a preliminary report. Cancer Res. 1958;18:121–34.PubMed

Kjellberg RN, Koehler AM, Preston WM, Sweet WH. Stereotaxic instrument for use with the Bragg peak of a proton beam. Confin Neurol. 1962;22:183–9.PubMedCrossRef

Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys. 2016;95:386–95 https://doi.org/10.1016/j.ijrobp.2016.02.036.PubMedCrossRefPubMedCentral

Phan J, Sio TT, Nguyen TP, Takiar V, Gunn GB, Garden AS, et al. Reirradiation of head and neck cancers with proton therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys. 2016;96:30–41 https://doi.org/10.1016/j.ijrobp.2016.03.053.PubMedCrossRef

Chao HH, Berman AT, Simone CB 2nd, Ciunci C, Gabriel P, Lin H, et al. Multi-institutional prospective study of reirradiation with proton beam radiotherapy for locoregionally recurrent non-small cell lung cancer. J Thorac Oncol. 2017;12:281–92 https://doi.org/10.1016/j.jtho.2016.10.018.PubMedCrossRef

Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, et al. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018;8:58–65 https://doi.org/10.1016/j.prro.2017.07.002.PubMedCrossRef

Oshiro Y, Mizumoto M, Okumura T, Fukuda K, Fukumitsu N, Abei M, et al. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. Radiother Oncol. 2017;123:240–5 https://doi.org/10.1016/j.radonc.2017.03.004.PubMedCrossRef

10.

Haaskogan D, Indelicato D, Paganetti H, Esiashvili N, Mahajan A, Yock T, et al. National Cancer Institute workshop on proton therapy for children: considerations regarding brainstem injury. Int J Radiat Oncol Biol Phys. 2018;101:152–68.CrossRef

11.

Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol. 2016;17:287–98 https://doi.org/10.1016/s1470-2045(15)00167-9.PubMedCrossRef

12.

Mouw KW, Sethi RV, Yeap BY, SM MD, Chen YL, Tarbell NJ, et al. Proton radiation therapy for the treatment of retinoblastoma. Int J Radiat Oncol Biol Phys. 2014;90:863–9 https://doi.org/10.1016/j.ijrobp.2014.07.031.PubMedCrossRefPubMedCentral

13.

Rombi B, Ares C, Hug EB, Schneider R, Goitein G, Staab A, et al. Spot-scanning proton radiation therapy for pediatric chordoma and chondrosarcoma: clinical outcome of 26 patients treated at Paul scherrer institute. Int J Radiat Oncol Biol Phys. 2013;86:578–84 https://doi.org/10.1016/j.ijrobp.2013.02.026.PubMedCrossRef

14.

Ares C, Albertini F, Frei-Welte M, Bolsi A, Grotzer MA, Goitein G, et al. Pencil beam scanning proton therapy for pediatric intracranial ependymoma. J Neuro-Oncol. 2016;128:137–45 https://doi.org/10.1007/s11060-016-2090-4.CrossRef

15.

Bishop AJ, Greenfield B, Mahajan A, Paulino AC, Okcu MF, Allen PK, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys. 2014;90:354–61 https://doi.org/10.1016/j.ijrobp.2014.05.051.PubMedCrossRefPubMedCentral

16.

Greenberger BA, Pulsifer MB, Ebb DH, SM MD, Jones RM, Butler WE, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2014;89:1060–8 https://doi.org/10.1016/j.ijrobp.2014.04.053.PubMedCrossRef

17.

McGovern SL, Okcu MF, Munsell MF, Kumbalasseriyil N, Grosshans DR, McAleer MF, et al. Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys. 2014;90:1143–52 https://doi.org/10.1016/j.ijrobp.2014.08.354.PubMedCrossRefPubMedCentral

18.

Weber DC, Murray FR, Correia D, Bolsi A, Frei-Welte M, Pica A, et al. Pencil beam scanned protons for the treatment of patients with Ewing sarcoma. Pediatr Blood Cancer. 2017;64 https://doi.org/10.1002/pbc.26688.

19.

Eaton BR, Esiashvili N, Kim S, Patterson B, Weyman EA, Thornton LT, et al. Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro-Oncology. 2016;18:881–7 https://doi.org/10.1093/neuonc/nov302.PubMedCrossRef

20.

Pulsifer MB, Sethi RV, Kuhlthau KA, SM MD, Tarbell NJ, Yock TI. Early cognitive outcomes following proton radiation in pediatric patients with brain and central nervous system tumors. Int J Radiat Oncol Biol Phys. 2015;93:400–7 https://doi.org/10.1016/j.ijrobp.2015.06.012.PubMedCrossRefPubMedCentral

21.

Yock TI, Bhat S, Szymonifka J, Yeap BY, Delahaye J, Donaldson SS, et al. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol. 2014;113:89–94 https://doi.org/10.1016/j.radonc.2014.08.017.PubMedCrossRefPubMedCentral

22.

Leiser D, Calaminus G, Malyapa R, Bojaxhiu B, Albertini F, Kliebsch U, et al. Tumour control and quality of life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy. Radiother Oncol. 2016;120:163–8 https://doi.org/10.1016/j.radonc.2016.05.013.PubMedCrossRef

23.

Bavle A, Tewari S, Sisson A, Chintagumpala M, Anderson M, Paulino AC. Meta-analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma. Pediatr Blood Cancer. 2018;65:e27095 https://doi.org/10.1002/pbc.27095.PubMedCrossRef

24.

Sethi RV, Shih HA, Yeap BY, Mouw KW, Petersen R, Kim DY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 2014;120:126–33 https://doi.org/10.1002/cncr.28387.PubMedCrossRef

25.

Maquilan G, Grover S, Alonso-Basanta M, Lustig RA. Acute toxicity profile of patients with low-grade gliomas and meningiomas receiving proton therapy. Am J Clin Oncol. 2014;37:438–43 https://doi.org/10.1097/COC.0b013e31827de86b.PubMedCrossRef

26.

Wilkinson B, Morgan H, Gondi V, Larson GL, Hartsell WF, Laramore GE, et al. Low levels of acute toxicity associated with proton therapy for low-grade glioma: a proton collaborative group study. Int J Radiat Oncol Biol Phys. 2016;96:E135 https://doi.org/10.1016/j.ijrobp.2016.06.930.PubMedCrossRef

27.

Shih HA, Sherman JC, Nachtigall LB, Colvin MK, Fullerton BC, Daartz J, et al. Proton therapy for low-grade gliomas: results from a prospective trial. Cancer. 2015;121:1712–9 https://doi.org/10.1002/cncr.29237.PubMedCrossRef

28.

MW MD, Plankenhorn DA, KP MM, Henderson MA, Dropcho EJ, Shah MV, et al. Proton therapy for atypical meningiomas. J Neuro-Oncol. 2015;123:123–8 https://doi.org/10.1007/s11060-015-1770-9.CrossRef

29.

Vlachogiannis P, Gudjonsson O, Montelius A, Grusell E, Isacsson U, Nilsson K, et al. Hypofractionated high-energy proton-beam irradiation is an alternative treatment for WHO grade I meningiomas. Acta Neurochir. 2017;159:2391–400 https://doi.org/10.1007/s00701-017-3352-4.PubMedCrossRef

30.

Stacchiotti S, Sommer J. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16:e71–83 https://doi.org/10.1016/s1470-2045(14)71190-8.PubMedCrossRef

31.

Weber DC, Badiyan S, Malyapa R, Albertini F, Bolsi A, Lomax AJ, et al. Long-term outcomes and prognostic factors of skull-base chondrosarcoma patients treated with pencil-beam scanning proton therapy at the Paul Scherrer Institute. Neuro-Oncology. 2016;18:236–43 https://doi.org/10.1093/neuonc/nov154.PubMedCrossRef

32.

Weber DC, Malyapa R, Albertini F, Bolsi A, Kliebsch U, Walser M, et al. Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol. 2016;120:169–74 https://doi.org/10.1016/j.radonc.2016.05.011.PubMedCrossRef

33.

Zhou J, Yang B, Wang X, Jing Z. Comparison of the effectiveness of radiotherapy with photons and particles for Chordoma after surgery: a meta-analysis. World Neurosurg. 2018;117:46–53 https://doi.org/10.1016/j.wneu.2018.05.209.PubMedCrossRef

34.

Feuvret L, Bracci S, Calugaru V, Bolle S, Mammar H, De Marzi L, et al. Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base: a retrospective, population-based study. Int J Radiat Oncol Biol Phys. 2016;95:312–21 https://doi.org/10.1016/j.ijrobp.2015.12.016.PubMedCrossRef

35.

Stieb S, Snider JW 3rd, Placidi L, Kliebsch U, Lomax AJ, Schneider RA, et al. Long-term clinical safety of high-dose proton radiation therapy delivered with pencil beam scanning technique for extracranial Chordomas and chondrosarcomas in adult patients: clinical evidence of spinal cord tolerance. Int J Radiat Oncol Biol Phys. 2018;100:218–25 https://doi.org/10.1016/j.ijrobp.2017.08.037.PubMedCrossRef

36.

Wattson DA, Tanguturi SK, Spiegel DY, Niemierko A, Biller BM, Nachtigall LB, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014;90:532–9 https://doi.org/10.1016/j.ijrobp.2014.06.068.PubMedCrossRef

37.

Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, et al. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiother Oncol. 2016;118:286–92 https://doi.org/10.1016/j.radonc.2015.12.008.PubMedCrossRefPubMedCentral

38.

Russo AL, Adams JA, Weyman EA, Busse PM, Goldberg SI, Varvares M, et al. Long-term outcomes after proton beam therapy for Sinonasal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2016;95:368–76 https://doi.org/10.1016/j.ijrobp.2016.02.042.PubMedCrossRef

39.

Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Mohammed K, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1027–38 https://doi.org/10.1016/s1470-2045(14)70268-2.PubMedCrossRef

40.

Chan A, Adams JA, Weyman E, Parambi R, Goldsmith T, Holman A, et al. A phase II trial of proton radiation therapy with chemotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2012;84:S151–S52.CrossRef

41.

Lewis GD, Holliday EB, Kocak-Uzel E, Hernandez M, Garden AS, Rosenthal DI, et al. Intensity-modulated proton therapy for nasopharyngeal carcinoma: decreased radiation dose to normal structures and encouraging clinical outcomes. Head Neck. 2016;38:E1886–E95.PubMedCrossRef

42.

Holliday EB, Garden AS, Rosenthal DI, Fuller CD, Morrison WH, Gunn GB, et al. Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of intensity-modulated proton therapy and intensity-modulated photon therapy. Int J Particle Ther. 2015;2:19–28 https://doi.org/10.14338/IJPT-15-00011.1.CrossRef

43.

Sio TT, Lin HK, Shi Q, Gunn GB, Cleeland CS, Lee JJ, et al. Intensity-modulated proton therapy (IMPT) versus intensity-modulated photon radiotherapy (IMRT) for oropharyngeal cancer: first comparative results of patient-reported outcomes. Int J Radiat Oncol Biol Phys. 2016;95:1107.PubMedCrossRefPubMedCentral

44.

Gunn GB, Blanchard P, Garden AS, Zhu XR, Fuller CD, Mohamed AS, et al. Clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys. 2016;95:360–7 https://doi.org/10.1016/j.ijrobp.2016.02.021.PubMedCrossRefPubMedCentral

45.

Blanchard P, Garden AS, Gunn GB, Rosenthal DI, Morrison WH, Hernandez M, et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - a case matched analysis. Radiother Oncol. 2016;120:48–55 https://doi.org/10.1016/j.radonc.2016.05.022.PubMedCrossRefPubMedCentral

46.

Lane AM, Kim IK, Gragoudas ES. Long-term risk of melanoma-related mortality for patients with uveal melanoma treated with proton beam therapy. Jama Ophthalmol. 2015;133:792–6 https://doi.org/10.1001/jamaophthalmol.2015.0887.PubMedCrossRef

47.

Seibel I, Cordini D, Rehak M, Hager A, Riechardt AI, Boker A, et al. Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome. Am J Ophthalmol. 2015;160:628–36 https://doi.org/10.1016/j.ajo.2015.06.017.PubMedCrossRef

48.

Papakostas TD, Lane AM, Morrison M, Gragoudas ES, Kim IK. Long-term outcomes after proton beam irradiation in patients with large choroidal melanomas. Jama Ophthalmol. 2017;135:1191–6 https://doi.org/10.1001/jamaophthalmol.2017.3805.PubMedCrossRefPubMedCentral

49.

Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radiol). 2016;28:e17–27 https://doi.org/10.1016/j.clon.2016.01.034.CrossRef

50.

Bensoussan E, Thariat J, Maschi C, Delas J, Schouver ED, Herault J, et al. Outcomes after proton beam therapy for large choroidal melanomas in 492 patients. Am J Ophthalmol. 2016;165:78–87 https://doi.org/10.1016/j.ajo.2016.02.027.PubMedCrossRef

51.

Holliday EB, Esmaeli B, Pinckard J, Garden AS, Rosenthal DI, Morrison WH, et al. A multidisciplinary orbit-sparing treatment approach that includes proton therapy for epithelial tumors of the orbit and ocular adnexa. Int J Radiat Oncol Biol Phys. 2016;95:344–52 https://doi.org/10.1016/j.ijrobp.2015.08.008.PubMedCrossRef

52.

Esmaeli B, Yin VT, Hanna EY, Kies MS, William WN Jr, Bell D, et al. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2016;38:1258–62 https://doi.org/10.1002/hed.24433.PubMedCrossRef

53.

Thariat J, Maschi C, Lanteri S, Peyrichon ML, Baillif S, Herault J, et al. Dry eye syndrome after proton therapy of ocular melanomas. Int J Radiat Oncol Biol Phys. 2017;98:142–51 https://doi.org/10.1016/j.ijrobp.2017.01.199.PubMedCrossRef

54.

Thariat J, Jacob S, Caujolle JP, Maschi C, Baillif S, Angellier G, et al. Cataract avoidance with proton therapy in ocular melanomas. Invest Ophthalmol Vis Sci. 2017;58:5378–86 https://doi.org/10.1167/iovs.17-22557.PubMedCrossRef

55.

Konstantinidis L, Roberts D, Errington RD, Kacperek A, Heimann H, Damato B. Transpalpebral proton beam radiotherapy of choroidal melanoma. Br J Ophthalmol. 2015;99:232–5 https://doi.org/10.1136/bjophthalmol-2014-305313.PubMedCrossRef

56.

Bush DA, Cheek G, Zaheer S, Wallen J, Mirshahidi H, Katerelos A, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University medical center. Int J Radiat Oncol Biol Phys. 2013;86:964–8 https://doi.org/10.1016/j.ijrobp.2013.05.002.PubMedCrossRef

57.

Chang JY, Zhang W, Komaki R, Choi NC, Chan S, Gomez D, et al. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017;122:274–80 https://doi.org/10.1016/j.radonc.2016.10.022.PubMedCrossRefPubMedCentral

58.

Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, et al. Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung Cancer. Int J Radiat Oncol Biol Phys. 2018;101:558–63 https://doi.org/10.1016/j.ijrobp.2018.02.022.PubMedCrossRef

59.

Nakayama H, Satoh H, Sugahara S, Kurishima K, Tsuboi K, Sakurai H, et al. Proton beam therapy of stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:979–84 https://doi.org/10.1016/j.ijrobp.2010.06.024.PubMedCrossRef

60.

Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115:367–72 https://doi.org/10.1016/j.radonc.2015.05.014.PubMedCrossRefPubMedCentral

61.

Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, et al. Proton beam radiotherapy and concurrent chemotherapy for Unresectable stage III non-small cell lung Cancer: final results of a phase 2 study. JAMA Oncol. 2017;3:e172032 https://doi.org/10.1001/jamaoncol.2017.2032.PubMedCrossRefPubMedCentral

62.

Oshiro Y, Okumura T, Kurishima K, Homma S, Mizumoto M, Ishikawa H, et al. High-dose concurrent chemo-proton therapy for stage III NSCLC: preliminary results of a phase II study. J Radiat Res. 2014;55:959–65 https://doi.org/10.1093/jrr/rru034.PubMedCrossRefPubMedCentral

63.

Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117:4707–13 https://doi.org/10.1002/cncr.26080.PubMedCrossRef

64.

Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung Cancer. J Clin Oncol. 2018;36:1813–22 https://doi.org/10.1200/jco.2017.74.0720.PubMedCrossRefPubMedCentral

65.

Liao Z. RTOG 1308 Phase III randomized trial comparing overall survival after photon versus proton chemoradiotherapy for inoperable stage II-IIIB NSCLC. Available from URL: https://clinicaltrials.gov/ct2/show/record/NCT01993810. Accessed 5 Sept 2018.

66.

Bush DA, Do S, Lum S, Garberoglio C, Mirshahidi H, Patyal B, et al. Partial breast radiation therapy with proton beam: 5-year results with cosmetic outcomes. Int J Radiat Oncol Biol Phys. 2014;90:501–5 https://doi.org/10.1016/j.ijrobp.2014.05.1308.PubMedCrossRef

67.

Verma V, Iftekaruddin Z, Badar N, Hartsell W, Han-Chih Chang J, Gondi V, et al. Proton beam radiotherapy as part of comprehensive regional nodal irradiation for locally advanced breast cancer. Radiother Oncol. 2017;123:294–8 https://doi.org/10.1016/j.radonc.2017.04.007.PubMedCrossRef

68.

Cuaron JJ, Chon B, Tsai H, Goenka A, DeBlois D, Ho A, et al. Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2015;92:284–91 https://doi.org/10.1016/j.ijrobp.2015.01.005.PubMedCrossRefPubMedCentral

69.

SM MD, Patel SA, Hickey S, Specht M, Isakoff SJ, Gadd M, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013;86:484–90 https://doi.org/10.1016/j.ijrobp.2013.01.038.CrossRef

70.

Stick LB, Yu J, Maraldo MV, Aznar MC, Pedersen AN, Bentzen SM, et al. Joint estimation of cardiac toxicity and recurrence risks after comprehensive nodal photon versus proton therapy for breast Cancer. Int J Radiat Oncol Biol Phys. 2017;97:754–61 https://doi.org/10.1016/j.ijrobp.2016.12.008.PubMedCrossRef

71.

Ishikawa H, Hashimoto T, Moriwaki T, Hyodo I, Hisakura K, Terashima H, et al. Proton beam therapy combined with concurrent chemotherapy for esophageal cancer. Anticancer Res. 2015;35:1757–62.PubMed

72.

Prayongrat A, Xu C, Li H, Lin SH. Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. Adv Radiat Oncol. 2017;2:301–7 https://doi.org/10.1016/j.adro.2017.06.002.PubMedCrossRefPubMedCentral

73.

Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal Cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017;99:667–76 https://doi.org/10.1016/j.ijrobp.2017.06.2450.PubMedCrossRef

74.

Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2017;99:128–35 https://doi.org/10.1016/j.ijrobp.2017.05.037.PubMedCrossRef

75.

Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat. 2015;47:34–45 https://doi.org/10.4143/crt.2013.218.PubMedCrossRef

76.

Hong TS, Wo JY, Yeap BY, Ben-Josef E, EI MD, Blaszkowsky LS, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34:460–8 https://doi.org/10.1200/jco.2015.64.2710.CrossRefPubMed

77.

Kimura K, Nakamura T, Ono T, Azami Y, Suzuki M, Wada H, et al. Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm. Hepatol Res. 2017;47:1368–74 https://doi.org/10.1111/hepr.12874.PubMedCrossRef

78.

Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys. 2016;95:477–82 https://doi.org/10.1016/j.ijrobp.2016.02.027.PubMedCrossRef

79.

Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, et al. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108:497–503 https://doi.org/10.1111/cas.13145.PubMedCrossRefPubMedCentral

80.

Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, et al. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol. 2014;190:806–14 https://doi.org/10.1007/s00066-014-0604-6.PubMedCrossRef

81.

Apisarnthanarax S, Saini J, O'Ryan-Blair A, Castro J, Bowen SR. Intensity modulated proton therapy with advanced planning techniques in a challenging hepatocellular carcinoma patient. Cureus. 2017;9:e1674 https://doi.org/10.7759/cureus.1674.PubMedPubMedCentral

82.

Takagi M, Demizu Y, Terashima K, Fujii O, Jin D, Niwa Y, et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017;6:2234–43 https://doi.org/10.1002/cam4.1159.PubMedCrossRefPubMedCentral

83.

Bryant C, Smith TL, Henderson RH, Hoppe BS, Mendenhall WM, Nichols RC, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;95:422–34 https://doi.org/10.1016/j.ijrobp.2016.02.038.PubMedCrossRef

84.

Ho CK, Bryant CM, Mendenhall NP, Henderson RH, Mendenhall WM, Nichols RC, et al. Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. Acta Oncol. 2018;57:582–8 https://doi.org/10.1080/0284186x.2018.1427886.PubMedCrossRef

85.

Henderson RH, Bryant C, Hoppe BS, Nichols RC, Mendenhall WM, Flampouri S, et al. Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. Acta Oncol. 2017;56:963–70 https://doi.org/10.1080/0284186x.2017.1287946.PubMedCrossRef

86.

Nakajima K, Iwata H, Ogino H, Hattori Y, Hashimoto S, Nakanishi M, et al. Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer. Int J Clin Oncol. 2018;23:353–60 https://doi.org/10.1007/s10147-017-1209-8.PubMedCrossRef

87.

Vargas CE, Hartsell WF, Dunn M, Keole SR, Doh L, Eisenbeisz E, et al. Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002. Am J Clin Oncol. 2018;41:115–20 https://doi.org/10.1097/coc.0000000000000241.PubMed

88.

Chung H, Polf J, Badiyan S, Biagioli M, Fernandez D, Latifi K, et al. Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer. J Appl Clin Med Phys. 2017;18:32–9 https://doi.org/10.1002/acm2.12001.PubMedCrossRef

89.

Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, et al. Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations. Phys Med Biol. 2017;62:1644–60 https://doi.org/10.1088/1361-6560/62/5/1644.PubMedCrossRef

90.

Group PTC-O. Particle therapy facilities in operation Available from URL: https://www.ptcog.ch/index.php/facilities-in-operation. Accessed 18 Sept 2018.

91.

Group PTC-O. Particle therapy facilities under construction. Available from URL: https://www.ptcog.ch/index.php/facilities-under-construction. Accessed 18 Sept 2018.

92.

Group PTC-O. Clinical trials for particle therapy. Available from URL: https://www.ptcog.ch/index.php/clinical-protocols. Accessed 13 Nov 2017.

93.

Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol. 2012;57:R99–117 https://doi.org/10.1088/0031-9155/57/11/r99.PubMedCrossRefPubMedCentral

94.

Bar E, Lalonde A, Royle G, Lu HM, Bouchard H. The potential of dual-energy CT to reduce proton beam range uncertainties. Med Phys. 2017;44:2332–44 https://doi.org/10.1002/mp.12215.PubMedCrossRef

95.

Bar E, Lalonde A, Zhang R, Jee KW, Yang K, Sharp G, et al. Experimental validation of two dual-energy CT methods for proton therapy using heterogeneous tissue samples. Med Phys. 2018;45:48–59 https://doi.org/10.1002/mp.12666.PubMedCrossRef

96.

Doolan PJ, Testa M, Sharp G, Bentefour EH, Royle G, Lu HM. Patient-specific stopping power calibration for proton therapy planning based on single-detector proton radiography. Phys Med Biol. 2015;60:1901–17 https://doi.org/10.1088/0031-9155/60/5/1901.PubMedCrossRef

97.

Arbor N, Dauvergne D, Dedes G, Letang JM, Parodi K, Quinones CT, et al. Monte Carlo comparison of x-ray and proton CT for range calculations of proton therapy beams. Phys Med Biol. 2015;60:7585–99 https://doi.org/10.1088/0031-9155/60/19/7585.PubMedCrossRef

98.

Hudobivnik N, Schwarz F, Johnson T, Agolli L, Dedes G, Tessonnier T, et al. Comparison of proton therapy treatment planning for head tumors with a pencil beam algorithm on dual and single energy CT images. Med Phys. 2016;43:495 https://doi.org/10.1118/1.4939106.PubMedCrossRef

99.

Giacometti V, Bashkirov VA, Piersimoni P, Guatelli S, Plautz TE, Sadrozinski HF, et al. Software platform for simulation of a prototype proton CT scanner. Med Phys. 2017;44:1002–16 https://doi.org/10.1002/mp.12107.PubMedCrossRef

100.

Sadrozinski HF, Geoghegan T, Harvey E, Johnson RP, Plautz TE, Zatserklyaniy A, et al. Operation of the preclinical head scanner for proton CT. Nucl Instrum Methods Phys Res A. 2016;831:394–9 https://doi.org/10.1016/j.nima.2016.02.001.PubMedCrossRefPubMedCentral

101.

Titt U, Sahoo N, Ding X, Zheng Y, Newhauser WD, Zhu XR, et al. Assessment of the accuracy of an MCNPX-based Monte Carlo simulation model for predicting three-dimensional absorbed dose distributions. Phys Med Biol. 2008;53:4455–70 https://doi.org/10.1088/0031-9155/53/16/016.PubMedCrossRefPubMedCentral

102.

Urie M, Goitein M, Holley WR, Chen GT. Degradation of the Bragg peak due to inhomogeneities. Phys Med Biol. 1986;31:1–15.PubMedCrossRef

103.

Yepes P, Adair A, Grosshans D, Mirkovic D, Poenisch F, Titt U, et al. Comparison of Monte Carlo and analytical dose computations for intensity modulated proton therapy. Phys Med Biol. 2018;63:045003 https://doi.org/10.1088/1361-6560/aaa845.PubMedCrossRefPubMedCentral

104.

Schmidt MA, Payne GS. Radiotherapy planning using MRI. Phys Med Biol. 2015;60:R323–61 https://doi.org/10.1088/0031-9155/60/22/r323.PubMedCrossRefPubMedCentral

105.

Flejmer AM, Edvardsson A, Dohlmar F, Josefsson D, Nilsson M, Witt Nystrom P, et al. Respiratory gating for proton beam scanning versus photon 3D-CRT for breast cancer radiotherapy. Acta Oncol. 2016;55:577–83 https://doi.org/10.3109/0284186x.2015.1120883.PubMedCrossRef

106.

Riboldi M, Orecchia R, Baroni G. Real-time tumour tracking in particle therapy: technological developments and future perspectives. Lancet Oncol. 2012;13:e383–91 https://doi.org/10.1016/s1470-2045(12)70243-7.PubMedCrossRef

107.

Lin M, Jolinta L, Feigenberg SJ, Mehta MP, Dsouza WD, Langen KM. Breath-hold intensity modulated proton therapy (BH-IMPT) for lung SBRT: feasibility study. Int J Radiat Oncol Biol Phys. 2014;90:S142–S42.CrossRef

108.

Kraan AC, van de Water S, Teguh DN, Al-Mamgani A, Madden T, Kooy HM, et al. Dose uncertainties in IMPT for oropharyngeal cancer in the presence of anatomical, range, and setup errors. Int J Radiat Oncol Biol Phys. 2013;87:888–96 https://doi.org/10.1016/j.ijrobp.2013.09.014.PubMedCrossRef

109.

Schwarz M. SP-0499: the need for adaptive approaches in proton therapy (compared to photons). Radiother Oncol. 2016;119:S237–S37.CrossRef

110.

Park YK, Sharp GC, Phillips J, Winey BA. Proton dose calculation on scatter-corrected CBCT image: feasibility study for adaptive proton therapy. Med Phys. 2015;42:4449–59 https://doi.org/10.1118/1.4923179.PubMedCrossRefPubMedCentral

111.

Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. Phys Med Biol. 2014;59:R419–72 https://doi.org/10.1088/0031-9155/59/22/r419.PubMedCrossRef

112.

Bronk JK, Guha-Thakurta N, Allen PK, Mahajan A, Grosshans DR, SL MG. Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma. Clin Transl Radiat Oncol. 2018;9:30–4 https://doi.org/10.1016/j.ctro.2018.01.002.PubMedCrossRefPubMedCentral

113.

Wouters BG, Skarsgard LD, Gerweck LE, Carabe-Fernandez A, Wong M, Durand RE, et al. Radiobiological intercomparison of the 160 MeV and 230 MeV proton therapy beams at the Harvard cyclotron laboratory and at Massachusetts General Hospital. Radiat Res. 2015;183:174–87 https://doi.org/10.1667/rr13795.1.PubMedCrossRef

114.

Maeda K, Yasui H, Matsuura T, Yamamori T, Suzuki M, Nagane M, et al. Evaluation of the relative biological effectiveness of spot-scanning proton irradiation in vitro. J Radiat Res. 2016;57:307–11 https://doi.org/10.1093/jrr/rrv101.PubMedCrossRefPubMedCentral

115.

Jones B. Clinical radiobiology of proton therapy: modeling of RBE. Acta Oncol. 2017;56:1374–8 https://doi.org/10.1080/0284186x.2017.1343496.PubMedCrossRef

116.

Mairani A, Dokic I, Magro G, Tessonnier T, Bauer J, Bohlen TT, et al. A phenomenological relative biological effectiveness approach for proton therapy based on an improved description of the mixed radiation field. Phys Med Biol. 2017;62:1378–95 https://doi.org/10.1088/1361-6560/aa51f7.PubMedCrossRef

117.

Zhang Y. Estimating end-of-range RBE in temporal lobe based on long-term flow-up data from patients with nasopharyngeal carcinoma. In: 57th PTCOG meeting; 2018.

Title: Proton beam therapy for cancer in the era of precision medicine
Authors: Man Hu
Liyang Jiang
Xiangli Cui
Jianguang Zhang
Jinming Yu
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2018
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-018-0683-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction

Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA

The biology and role of CD44 in cancer progression: therapeutic implications

Keynote webinar | Spotlight on antibody–drug conjugates in cancer